AI English summary of an SEC filing — figures as filed
Baxter International BAXThe company said Q1 2026 sales from continuing operations were approximately $2.7 billion, up 3% on a reported basis and down 1% on an organic basis. U.S. sales were approximately $1.44 billion, down 4%, and international sales were approximately $1.27 billion, up 12%.
Key points
AI summaryThe company said Q1 2026 sales from continuing operations were approximately $2.7 billion, up 3% on a reported basis and down 1% on an organic basis. U.S. sales were approximately $1.44 billion, down 4%, and international sales were approximately $1.27 billion, up 12%.
The company said that for Q1 2026, its U.S. GAAP net loss from continuing operations was ($17) million, or a loss of ($0.03) per diluted share, and that adjusted diluted EPS was $0.36, down 35%. It cited the timing shift in expense recognition from the prior year, tariff-related costs, and higher manufacturing costs, including lower absorption, as factors.
The company said Medical Products & Therapies sales for Q1 2026 were $1,285 million, up 2% on a reported basis and down 2% on an organic basis. Drug Compounding sales in the same quarter were $320 million, up 30%, while Injectables & Anesthesia sales were $301 million, down 10%.
The company said it reiterated its full-year outlook, with reported sales growth of flat to 1%, organic sales growth of approximately flat, and adjusted diluted EPS of $1.85 to $2.05. Its board declared a quarterly cash dividend of $0.01 per share effective April 29, 2026, payable on July 1, 2026.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q1 2026 Continuing Operations Sales $2.7 billion
The company said Q1 2026 sales from continuing operations were approximately $2.7 billion, up 3% on a reported basis and down 1% on an organic basis. U.S. sales were approximately $1.44 billion, down 4%, and international sales were approximately $1.27 billion, up 12%.
Source · Based on the filing body and exhibits
GAAP Loss From Continuing Operations ($0.03) Per Share, Adjusted EPS $0.36
The company said that for Q1 2026, its U.S. GAAP net loss from continuing operations was ($17) million, or a loss of ($0.03) per diluted share, and that adjusted diluted EPS was $0.36, down 35%. It cited the timing shift in expense recognition from the prior year, tariff-related costs, and higher manufacturing costs, including lower absorption, as factors.
Source · Based on the filing body and exhibits
Q1 2026 Segment Sales Changes
The company said Medical Products & Therapies sales for Q1 2026 were $1,285 million, up 2% on a reported basis and down 2% on an organic basis. Drug Compounding sales in the same quarter were $320 million, up 30%, while Injectables & Anesthesia sales were $301 million, down 10%.
Source · Based on the filing body and exhibits
2026 Outlook Reaffirmed and Quarterly Dividend $0.01
The company said it reiterated its full-year outlook, with reported sales growth of flat to 1%, organic sales growth of approximately flat, and adjusted diluted EPS of $1.85 to $2.05. Its board declared a quarterly cash dividend of $0.01 per share effective April 29, 2026, payable on July 1, 2026.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…